This article is more than 5 years old. Information may no longer be current.
Encouraging phase 2 results observed for polypoidal choroidal vasculopathy treatment
Click Here to Manage Email Alerts
SOUTH SAN FRANCISCO, Calif. — A phase 2 analysis of a treatment for polypoidal choroidal vasculopathy has returned promising results, according to a press release from OXiGENE.
The FAVOR study is a multicenter, placebo-controlled, double-masked analysis of 20 Asian patients, the release said. It compared single intravenous injections of different doses of Zybrestat (fosbretabulin) with placebo in patients with polypoidal choroidal vasculopathy. Retinas of the subjects were imaged at days 2, 8, 15 and 28 after the injection.
The study's primary objective was to note the change in the number of polyps after the injection, according to the release. While the number did not change after the injections, there were suggestions of a decrease in polyp activity and a reduction in subretinal fluid and retinal edema in subjects who received fosbretabulin injections.
"These results suggest that continued evaluation of Zybrestat in patients with [polypoidal choroidal vasculopathy] is warranted, possibly with a topical formulation that has undergone initial preclinical testing," Timothy Lai, MD, FRCS, FRCOphth, said in presenting the study's findings at the 6th Asia-Pacific Vitreoretina Society Congress in Hyderabad, India, according to the release.